All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
On August 31, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to tolinapant (formerly ASTX660) for the treatment of T-cell lymphoma.1
Tolinapant is an orally administered, dual antagonist of the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP-1 and cIAP-2) and the X-linked inhibitor of apoptosis protein (XIAP).
Tolinapant is currently under evaluation in a phase I/II study (NCT02503423). The phase I portion of the study aimed to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the safety of the drug at the RP2D. Tolinapant was orally administered once per day, on a 1-week-on/1-week-off schedule during 28-day cycles. The observed MTD was 210 mg/day and the RP2D was set at 180 mg/day. Tolinapant was generally well tolerated at doses ≤ 180 mg/day with no drug-related Grade ≥ 3 adverse events (AEs) at this dose level, and with the most common drug-related AEs being nausea (22%), pruritus (18%), and vomiting (18%).2
Preliminary results from the ongoing phase II of the study showed evidence of the clinical activity of tolinapant in a patient with cutaneous T-cell lymphoma.2 The final results of the phase II part of the study remain unpublished.
Francine Foss | ASCO 2018 | Novel therapies for CTCL
Francine Foss | ASCO 18 | Novel therapies for CTCL
AACR 2017 | Poster 4589/4 – Preclinical investigation of the novel SGN-CD70A antibody drug conjugate in T-Cell Lymphomas
At AACR 2017, one of the posters on display (4589 / 4) was titled “Preclinical investigation of SGN-CD70A antibody-drug conjugate...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox